Literature DB >> 9082363

[Cytokeratin expression of benign and malignant epithelial thyroid gland tumors. An immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies].

S Schröder1, A Wodzynski, B Padberg.   

Abstract

Using 8 different monoclonal antibodies, immunohistology was performed on 36 follicular adenomas and on 28 follicular, 34 papillary, 27 medullary and 29 anaplastic carcinomas of the thyroid. The panel of antibodies was directed against broad-spectrum cytokeratins (pan-CK, antibody lu-5), against basic and acid high-molecular-weight CK of types #1, 5, 10 and 14, against basic (#5 and 6) and acid high-molecular-weight CK (#13) and against basic (#7 and #8) and acid low-molecular-weight CK (#19 and #20). With the exception of a large number of anaplastic carcinomas, nearly all other tumours exhibited strong immunoreactivity with antibodies against pan-CK, CK 8 and CK 19. CK 20 expression was exclusively shown for 2 medullary carcinomas. Reactivity for high-molecular-weight CK could only, each time focally, be demonstrated for 14 papillary and 2 follicular carcinomas and for 2 anaplastic carcinomas with partial squamous differentiation. Thirteen anaplastic carcinomas were not decorated by any of the CK antibodies applied. CK 7 staining exceeding the staining of individual cells was observed in 26 papillary cancers. In contrast, such a finding could only be obtained with each one follicular adenoma, medullary carcinoma and anaplastic carcinoma and with 5 follicular carcinomas. These results confirm earlier studies in that CK 20 expression among thyroid tumours is restricted to the neuroendocrine medullary carcinomas and that in a larger percentage of anaplastic thyroid carcinomas an epithelial phenotype can not be demonstrated even upon using broad-spectrum CK antibodies. New is the finding that there exist considerable differences between papillary carcinomas and all other non-papillary thyroid tumours regarding CK 7 expression. This result might be of differential diagnostic value for the distinction of follicular and papillary thyroid neoplasias which sometimes have an overlapping histological pattern.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9082363     DOI: 10.1007/s002920050181

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  8 in total

1.  The role of cytokeratin 19 in the differential diagnosis of true papillary carcinoma of thyroid and papillary carcinoma-like changes in Graves' disease.

Authors:  Suna Erkiliç; N Emrah Koçer
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

2.  Metastasis of liver cancer to the thyroid after surgery: A case report.

Authors:  Hao-Chen Zhong; Zhao-Wei Sun; Guang-Hua Cao; Wei Zhao; Kai Ma; Bing-Yuan Zhang; Yu-Jie Feng
Journal:  World J Clin Cases       Date:  2022-05-26       Impact factor: 1.534

3.  Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid.

Authors:  Suna Erkiliç; Abdullah Aydin; N Emrah Koçer
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

4.  Metastasis of non-muscle-invasive bladder cancer into the thyroid gland: a literature review accompanied by a rare case.

Authors:  Murat Tuncer; Gokhan Faydaci; Gokhan Altin; Banu Atalay Erdogan; Sermin Kibar; Arif Sanli; Dilek Bilgici
Journal:  Korean J Urol       Date:  2014-03-13

5.  Expression of cytokeratin 20 in thyroid carcinomas and peripheral blood detected by reverse transcription polymerase chain reaction.

Authors:  T Weber; J Lacroix; J Weitz; K Amnan; A Magener; T Hölting; E Klar; C Herfarth; M von Knebel Doeberitz
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

6.  Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer.

Authors:  L Giovanella; M Imperiali; P Trimboli
Journal:  Sci Rep       Date:  2017-08-04       Impact factor: 4.379

7.  Evaluation of CYFRA 21.1 as a Dedifferentiation Marker of Advanced Thyroid Cancer.

Authors:  Sumeet Suresh Malapure; Chetan D Patel; R Lakshmy; Chandrashekhar Bal
Journal:  Indian J Nucl Med       Date:  2020-03-12

8.  Increased PADI4 expression in blood and tissues of patients with malignant tumors.

Authors:  Xiaotian Chang; Jinxiang Han; Li Pang; Yan Zhao; Yi Yang; Zhonglin Shen
Journal:  BMC Cancer       Date:  2009-01-30       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.